



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.elsevier.com/locate/jff

Limonoids isolated from *Toona sinensis* and their radical scavenging, anti-inflammatory and cytotoxic activities

Jiang Hu ^{a,*}, Yan Song ^{b,§}, Xia Mao ^a, Zhen-Ji Wang ^c, Qin-Jie Zhao ^{d,**}

^a College of Biological Resources and Environment Science, Qujing Normal University, Qujing 655011, China

^b Department of Pharmacy, 455 Hospital of People's Liberation Army, Shanghai 200052, China

^c Department of Chemistry and Life Science, Chuxiong Normal University, Chuxiong 675000, China

^d Department of Organic Chemistry, College of Pharmacy, Second Military Medical University, Shanghai 200433, China

ARTICLE INFO

Article history:

Received 5 August 2015

Received in revised form 1 October 2015

Accepted 13 October 2015

Available online 10 November 2015

Keywords:

Toona sinensis

Meliaceae

Limonoids

Radical scavenging

Anti-inflammatory

Cytotoxic activities

ABSTRACT

A phytochemical investigation of the ethanol extract of *Toona sinensis* (A. Juss.) Roem resulted in the isolation of ten new limonoids, toonasinenines A–J (1–10), together with two known compounds, toonafolin (11) and toonacilianin D (12). Their structures were determined by spectroscopic analyses. The isolated components were evaluated *in vitro* for radical scavenging potential using ABTS⁺ and DPPH test, anti-inflammatory activities for Cox-1 and Cox-2, and cytotoxicities against nine tumour cell lines (A549, BGC-823, CHG-5, HCT15, HeLa, HepG2, MDA-MB-231, SHG-44 and SGC-7901 cells). As a result, 4, 5 and 7–10 showed potent radical scavenging activities, while limonoids 1–4 and 11 exhibited significant anti-inflammatory and cytotoxic potential.

© 2015 Elsevier Ltd. All rights reserved.

1. Introduction

Toona sinensis (A. Juss.) Roem (Meliaceae), a perennial deciduous arbour, is widely distributed in eastern Asia (Edmonds & Staniforth, 1998). The leaves of *T. sinensis*, which contain a distinct flavour, are very popular in vegetarian cuisine and have

long been used as a nutritious food in China and Malaysia and as animal fodder in India (Chen, Liang, Huang, & Huang, 2015). Almost every part of *T. sinensis*, including seeds, bark, root bark, petioles, and especially leaves, has a medicinal effect (Chang et al., 2006). The bark is used as astringent and depurative substance, the powdered root is used as a corrective, and the fruits are applied for the treatment of eye infection and used as an

* Corresponding author. College of Biological Resources and Environment Science, Qujing Normal University, Qujing 655011, China. Tel.: +86 874 8998627; fax: +86 874 8998627.

E-mail address: hujiang@mail.kib.ac.cn (J. Hu).

** Corresponding author. Department of Organic Chemistry, College of Pharmacy, Second Military Medical University, Shanghai 200433, China. Tel.: +86 21 81871228; fax: +86 21 81871228.

E-mail address: qjzhao@smmu.edu.cn (Q.-J. Zhao).

§ These authors contributed equally to the article.

<http://dx.doi.org/10.1016/j.jff.2015.10.009>

1756-4646/© 2015 Elsevier Ltd. All rights reserved.

astrigent. Leaves possess anti-inflammatory, antidoting, and worm-killing effects and are used in folk medicine to treat enteritis, dysentery, carbuncles, boils, dermatitis, scabies, tinea blanca, and especially abdominal tumours (Hsiang et al., 2013; Malairajan, Gopalakrishnan, Narasimhan, Veni, & Kavimani, 2007). Previous pharmacological and bioactivity studies on the extract of *T. sinensis* leaves have revealed anti-cancer (Chen, Chien, Huang, & Chia, 2014), anti-sepsis (Yang, Chen, Tsai, Huang, & Wang, 2014), antimicrobial (Wu et al., 2014), antinociceptive (Su et al., 2015), anti-inflammation (Hseu et al., 2011), anti-diabetes (Hsieh et al., 2012), antioxidant (Chen, Huang, Lin, Hsu, & Chung, 2013), and α -glucosidase inhibitory activities (Zhao, Zhou, Chen, & Wang, 2009). *T. sinensis* leaf extract inhibits microglia-mediated neuroinflammation (Wang, Tsai, Hsieh, Lin, & Lin, 2014), Leydig cell steroidogenesis (Poon, Leu, Hsu, Liu, & Huang, 2005) and severe acute respiratory syndromes (SARS) coronavirus replication (Chen et al., 2008). It also inhibits lipid accumulation and fatty acid oxidation in adipocytes (Liu, Tsai, & Chang, 2014). The safety profile and nonmutagenic characteristics of the extracts from *T. sinensis* have been evaluated using acute and sub-acute toxicity studies in mice and rat (Liao, Yeh, Lin, Wei, & Chung, 2009). Because of the pharmacological properties of *T. sinensis* leaves, the study of the chemical composition has been of particular interest. Currently, phytochemical studies have shown the presence of limonoids, flavonoids, phytols, coumarins and norcysteine derivative (Cheng et al., 2009). However, these studies mainly focus on the high polar extracts and volatile compounds. To find more pharmacologically and structurally interesting substances, the present investigation led to ten new limonoids, toonasinenines A–J (1–10), and 2 known compounds, toonafolin (11) and toonacilianin D (12) (Fig. 1). The structures of these com-

pounds were elucidated mainly by nuclear magnetic resonance (NMR) spectroscopic and mass spectroscopic (MS) methods. Furthermore, all the limonoids were evaluated *in vitro* for their radical scavenging, anti-inflammatory and cytotoxic potential.

2. Materials and methods

2.1. General

Optical rotations were recorded on a Perkin-Elmer 341 polarimeter. IR spectra were taken on a Perkin-Elmer 577 spectrometer with KBr disks. NMR spectra were recorded on a Bruker AM-400 spectrometer. The coupling constants (J) were in Hz and chemical shift values (δ) were given in ppm with TMS as internal standard. ESI-MS and HR-ESI-MS spectra were obtained on an Esquire 3000plus (Bruker Daltonics) and a Finnigan LC QDECA instrument. Column chromatographic separations were performed with silica gel (200–300 mesh and H60, Qingdao Haiyang Chemical Group Corporation, China), MCI gel CHP20P (75–150 μ m, Mitsubishi Chemical Industries, Tokyo, Japan), and Sephadex LH-20 (Pharmacia Biotech AB, Uppsala, Sweden) as packing materials. TLC was carried out on precoated silica gel GF₂₅₄ plates (Yantai Chemical Industries, Yantai, China). The TLC spots were visualised using 5% sulphuric acid in alcohol containing 10 mg/mL vanillin and viewed at 254 nm. Analytical HPLC was performed on a Waters 2690 instrument with a 996 PAD (photodiode array detector) with an Alltech ELSD 2000 detector. Semipreparative and preparative HPLC was carried out on a Varian SD1 instrument coupled with a 320 single-wave detector. Their chromatographic separations were taken on C-18 columns (250 \times 10 mm, 5 μ m, Waters, Massachusetts, USA;




Fig. 1 – The structures of limonoids 1–12.

220 × 25 mm, 10 μm, Merck, Darmstadt, Germany, respectively), with a gradient solvent system composed of MeOH and H₂O, using a flow rate of 3.0 and 15.0 mL/min, respectively.

2.2. Plant material

The leaves of *T. sinensis* were collected in the suburb of Qujing, Yunan Province, China, in May 2014. A specimen (TS20140501), identified by one of the authors (X. Mao), was deposited in the Herbarium of the College of Biological Resources and Environment Science, Qujing Normal University, Qujing, China.

2.3. Extraction and isolation

The air-dried leaves of *T. sinensis* (5.0 kg) were ground into powder (80 mesh) and extracted with EtOH–H₂O (95:5, v/v, 20 L) at ambient temperature three times (each for 7 days). After removal of solvent under reduced pressure, the crude extract (410 g) was partitioned between EtOAc and H₂O to afford an EtOAc-soluble fraction (100 g) which was chromatographed on a silica gel column (1.5 kg) with CHCl₃–MeOH mixtures (0:1, 100:1, 50:1, 20:1, 8:1, and 1:1, v/v) as elutant to obtain six fractions (F₁–F₆). F₃ (5.9 g) was subjected to a MCI gel (MeOH–H₂O, 50:50–90:10, v/v) to yield four subfractions (F_{3a}–F_{3d}). F_{3a} (298 mg) was purified on reverse phase HPLC column eluting with methanol/water (65:35, v/v) to provide **7** (30 mg) and **12** (28 mg). F_{3b} (226 mg) was separated on a column of C₁₈ silica gel (MeOH–H₂O, 45:55–60:40, v/v) followed by Sephadex LH-20 (CHCl₃/MeOH, 1:1, v/v), furnishing **8** (37 mg). F_{3c} (412 mg) was chromatographed on a preparative RP-HPLC column eluting with methanol/water (55:45, v/v) to afford **4** (43.7 mg) and **6** (37.1 mg). F₄ (3.5 g) was applied to silica gel cc (petroleum ether–acetone; 4:1–1:1, v/v) to give five subfractions (F_{4a}–F_{4e}). F_{4b} (698 mg) was separated on a SiO₂ column with PE/Me₂CO (2:1, v/v) as mobile phase and further purified on a preparative RP-HPLC column eluting with methanol/water (55:45, v/v) to afforded **1** (33.7 mg) and **3** (24.6 mg). F_{4c} (963 mg) was subjected to silica gel CC with CHCl₃–MeOH mixtures (50:1 and 30:1, v/v) as elutant to yield **5** (27 mg) and **10** (26.1 mg). F_{4d} (897 mg) was applied to a column of reversed-phase silica gel (MeOH–H₂O, 50:50, v/v) to yield four fractions F_{4d1}–F_{4d4}. Further chromatography of F_{4d2} (706 mg) on SiO₂ column eluting with CHCl₃/MeOH (95:5, v/v) and then purified by preparative HPLC, with CH₃CN–H₂O (1:1, v/v) as mobile phase, gave **2** (27 mg) and **9** (19 mg). F_{4d3} (249 mg) was separated on SiO₂ column eluting with CHCl₃/MeOH (95:5, v/v) and on Sephadex LH-20 column (CHCl₃/MeOH, 1:1, v/v) to produce **11** (43 mg).

2.3.1. Toonasinenine A (1)

White amorphous powder, C₂₉H₃₈O₉, [α]_D²⁵ –66.1 (c 0.25, MeOH), UV (MeOH) λ_{max} (log ε): 210 (3.13) nm, IR (KBr) ν_{max}: 3435, 2925, 1715, 1643, 1375, 1232, 797 cm⁻¹, ¹H and ¹³C NMR data see Table 1, ESI-MS *m/z*: 553 ([M + Na]⁺), HR-ESI-MS: *m/z* 553.2408 ([M + Na]⁺, C₂₉H₃₈O₉Na, calc. 553.2414).

2.3.2. Toonasinenine B (2)

White amorphous powder, C₂₇H₃₂O₈, [α]_D²⁵ –30.3 (c 0.24, MeOH), UV (MeOH) λ_{max} (log ε): 210 (3.63), 259 (4.49) nm, IR (KBr) ν_{max}: 3433, 2949, 1740, 1721, 1681, 1636, 1394, 1210, 1030 cm⁻¹, ESI-MS

m/z: 485 ([M + H]⁺), HR-ESI-MS: *m/z* 485.2179 ([M + H]⁺, C₂₇H₃₃O₈, calc. 485.2175).

2.3.3. Toonasinenine C (3)

White amorphous powder, C₃₃H₄₂O₁₃, [α]_D²⁵ +40.2 (c 0.15, MeOH), UV (MeOH) λ_{max} (log ε): 207 (3.06) nm, IR (KBr) ν_{max}: 3434, 2921, 1740, 1637, 1377 1232, 1072, 599 cm⁻¹, ESI-MS *m/z*: 669 ([M + Na]⁺), HR-ESI-MS: *m/z* 669.2517 ([M + Na]⁺, C₃₃H₄₂O₁₃Na, calc. 669.2523).

2.3.4. Toonasinenine D (4)

White amorphous powder, C₂₅H₃₂O₁₀, [α]_D²⁵ +44.2 (c 0.10, MeOH), UV (MeOH) λ_{max} (log ε): 207 (4.05) nm, IR (KBr) ν_{max}: 3423, 2918, 2852, 1630, 1389, 1157, 1068, 1018 cm⁻¹, ¹H and ¹³C NMR data see Table 1, ESI-MS *m/z*: 515 ([M + Na]⁺), HR-ESI-MS: *m/z* 515.1887 ([M + Na]⁺, C₂₅H₃₂O₁₀Na, calc. 515.1893).

2.3.5. Toonasinenine E (5)

White amorphous powder, C₂₉H₃₆O₈, [α]_D²⁵ +70.6 (c 0.12, MeOH), UV (MeOH) λ_{max} (log ε): 206 (3.86) nm, IR (KBr) ν_{max}: 3423, 2925, 1743, 1674, 1381, 1245, 1043 cm⁻¹, ¹H and ¹³C NMR data see Table 1, ESI-MS *m/z*: 535 ([M + Na]⁺), HR-ESI-MS: *m/z* 535.2303 ([M + Na]⁺, C₂₉H₃₆O₈Na, calc. 535.2308).

2.3.6. Toonasinenine F (6)

White amorphous powder, C₂₇H₃₈O₉, [α]_D²⁵ +70.6 (c 1, MeOH), UV (MeOH) λ_{max} (log ε): 206 (3.86) nm, IR (KBr) ν_{max}: 3450, 2925, 1717, 1628, 1441, 1381, 1298, 1030, 600 cm⁻¹, ¹H and ¹³C NMR data see Table 1, ESI-MS *m/z*: 529 ([M + Na]⁺), HR-ESI-MS: *m/z* 529.2413 ([M + Na]⁺, C₂₇H₃₈O₉Na, calc. 529.2414).

2.3.7. Toonasinenine G (7)

White amorphous powder, C₂₇H₃₆O₈, [α]_D²⁵ –41.3 (c 0.09, MeOH), UV (MeOH) λ_{max} (log ε): 238 (4.11) nm, IR (KBr) ν_{max}: 3602, 3449, 2924, 1725, 1622, 1247, 1157, 1024, 874 cm⁻¹, ¹H and ¹³C NMR data see Table 1, ESI-MS *m/z*: 489 ([M + H]⁺), HR-ESI-MS: *m/z* 489.2483 ([M + H]⁺, C₂₇H₃₇O₈, calc. 489.2488).

2.3.8. Toonasinenine H (8)

White amorphous powder, C₂₇H₃₈O₆, [α]_D²⁵ –8.1 (c 0.12, MeOH), UV (MeOH) λ_{max} (log ε): 280 (3.16) nm, IR (KBr) ν_{max}: 3434, 2950, 1735, 1647, 1457, 1376, 1245, 1165, 1026, 874 cm⁻¹, ESI-MS *m/z*: 481 ([M + Na]⁺), HR-ESI-MS: *m/z* 481.2560 ([M + Na]⁺, C₂₇H₃₈O₆Na, calc. 481.2566).

2.3.9. Toonasinenine I (9)

White amorphous powder, C₂₇H₃₆O₈, [α]_D²⁵ –53.9 (c 0.10, MeOH), UV (MeOH) λ_{max} (log ε): 225 (3.55) nm, IR (KBr) ν_{max}: 3528, 2921, 1743, 1645, 1232, 602 cm⁻¹, ¹H and ¹³C NMR data see Table 1, ESI-MS *m/z*: 511 ([M + Na]⁺), HR-ESI-MS: *m/z* 511.2303 ([M + Na]⁺, C₂₇H₃₆O₈Na, calc. 511.2308).

2.3.10. Toonasinenine J (10)

White amorphous powder, C₃₀H₃₈O₇, [α]_D²⁵ –57.2 (c 0.15, MeOH), UV (MeOH) λ_{max} (log ε): 225 (4.11) nm, IR (KBr) ν_{max}: 3563, 2934, 1730, 1700, 1615, 1385, 1157, 797 cm⁻¹, ESI-MS *m/z*: 497 ([M + H]⁺), HR-ESI-MS: *m/z* 511.2693 ([M + H]⁺, C₃₀H₃₉O₇, calc. 511.2696).

Table 1 – ¹H NMR (400 MHz) and ¹³C NMR (100 MHz) data for compounds 1, 4–7 and 9: δ in ppm in CD₂OD (multiplicities, J in Hz).

| No. | 1 | | 4 | | 5 | | 6 | | 7 | | 9 | |
|-----------------------------------|-----------------------|---------------------|-----------------------|---------------------|-----------------------|---------------------|-----------------------|---------------------|-----------------------|---------------------|-----------------------|---------------------|
| | δ_{H} | δ_{C} | δ_{H} | δ_{C} | δ_{H} | δ_{C} | δ_{H} | δ_{C} | δ_{H} | δ_{C} | δ_{H} | δ_{C} |
| 1 | 3.80, dd (11.4, 5.0) | 85.5 | | 107.5 | 7.30, d (10.7) | 155.7 | 3.23, d (4.3) | 57.9 | 6.80, d (10.0) | 152.6 | 6.28, d (11.8) | 150.1 |
| 2 _{α} | 2.95, dd (15.8, 11.4) | 42.9 | 2.66, dd (14.2, 13.7) | 44.5 | 6.01, d (10.7) | 127.3 | | 58.2 | 5.97, d (10.0) | 124.6 | 5.97, d (11.8) | 121.5 |
| 2 _{β} | 2.66, overlapped | | 2.01, dd (14.2, 4.4) | | | | 3.11, m | | | | | |
| 3 | | 208.8 | 4.34, dd (13.7, 4.4) | 70.8 | | 207.1 | 3.69, d (2.8) | 74.0 | | 204.8 | | 166.7 |
| 4 | | 53.8 | | 95.5 | | 59.5 | | 39.4 | | 46.5 | | 83.6 |
| 5 | 2.66, overlapped | 52.1 | | 84.0 | 2.54, s | 48.5 | 2.34, s | 49.8 | 2.46, s | 48.8 | 2.48, s | 51.2 |
| 6 _{α} | 2.63, dd (16.5, 1.8) | 32.9 | 3.89, s | 78.3 | 4.61, s | 72.5 | 4.42, s | 72.8 | 4.69, s | 71.2 | 4.69, s | 70.1 |
| 6 _{β} | 3.28, dd (16.5, 8.6) | | | | | | | | | | | |
| 7 | | 173.8 | | 176.5 | | 178.4 | | 182.2 | | 177.1 | | 176.7 |
| 8 | | 76.7 | | 76.7 | | 139.0 | | 78.0 | | 77.8 | | 77.0 |
| 9 | 2.73, d (11.5) | 63.5 | 3.17, d (12.5) | 55.9 | 2.68, d (11.5) | 57.5 | 2.61, d (11.5) | 46.7 | 2.33, d (11.5) | 44.9 | 2.39, d (11.5) | 52.1 |
| 10 | | 49.0 | | 56.4 | | 42.0 | | 41.7 | | 44.1 | | 49.1 |
| 11 _{α} | | 76.5 | | 74.5 | | 70.8 | 2.13, m | 35.3 | 2.21, m | 27.7 | 1.79, m | 24.7 |
| 11 _{β} | 3.95, m | | 4.27, m | | 5.16, m | | 2.02, m | | 2.07, m | | 1.39, m | |
| 12 _{α} | 1.62, dd (15.5, 5.6) | 41.0 | 1.55 dd (13.0, 6.6) | 46.7 | 1.86, dd (15.5, 11.6) | 42.8 | | 77.2 | | 62.1 | 1.55, dd (15.5, 11.2) | 35.3 |
| 12 _{β} | 2.44, dd (15.5, 11.6) | | 2.36, dd (13.0, 10.6) | | 1.92, dd (15.5, 5.6) | | 4.07, dd (13.5, 10.8) | | 4.08, dd (15.5, 11.6) | | 1.94, dd (15.5, 5.4) | |
| 13 | | 41.6 | | 42.9 | | 45.4 | | 47.8 | | 45.9 | | 41.0 |
| 14 | | 74.3 | | 73.8 | | 73.3 | | 76.5 | | 74.6 | | 74.6 |
| 15 | 3.46, s | 54.9 | 3.58, s | 57.2 | 4.06, s | 62.1 | 3.54, s | 56.9 | 3.47, s | 54.2 | 3.46, s | 54.4 |
| 16 _{α} | 1.81, dd (13.2, 6.6) | 31.3 | 1.87, dd (13.2, 6.6) | 32.5 | 2.00, dd (13.4, 11.0) | 32.1 | 1.89, dd (13.4, 11.2) | 33.4 | 1.79, m | 31.7 | 1.80, dd (13.2, 10.9) | 31.8 |
| 16 _{β} | 2.28, dd (13.2, 11.2) | | 2.21, dd (13.2, 11.2) | | 2.19, dd (13.4, 6.5) | | 2.20, dd (13.4, 6.4) | | 2.31, m | | 2.25, dd (13.2, 6.4) | |
| 17 | 2.76, dd (11.2, 6.6) | 41.2 | 2.74, dd (11.2, 6.6) | 43.6 | 2.63, dd (11.0, 6.5) | 41.4 | 2.73, dd (11.2, 6.4) | 44.0 | 2.77, dd (10.8, 6.4) | 41.3 | 2.74, dd (10.9, 6.4) | 41.3 |
| 18 | 1.05, s | 19.6 | 1.07, s | 23.9 | 0.71, s | 19.9 | 0.93, s | 16.6 | 0.84, s | 15.3 | 0.97, s | 22.7 |
| 19 | 1.08, s | 21.8 | 1.44, s | 13.5 | 1.22, s | 21.3 | 1.57, s | 19.4 | 1.76, s | 19.1 | 1.45, s | 21.0 |
| 20 | | 122.7 | | 124.9 | | 124.8 | | 125.4 | | 123.3 | | 123.0 |
| 21 | 7.15, br s | 139.3 | 7.32, s | 141.3 | 7.21, s | 141.4 | 7.24, s | 141.2 | 7.08, s | 139.0 | 7.13, s | 139.2 |
| 22 | 6.21, br s | 110.5 | 6.35, br s | 112.7 | 6.25, br s | 112.6 | 6.40, br s | 112.9 | 6.22, br s | 110.8 | 6.17, br s | 110.6 |
| 23 | 7.41, s | 143.1 | 7.42, br s | 144.4 | 7.44, br s | 144.9 | 7.39, br s | 144.3 | 7.35, br s | 142.7 | 7.36, br s | 142.9 |
| 28 | 1.02, s | 19.8 | 1.55, s | 15.8 | 1.07, s | 22.4 | 0.85, s | 30.5 | 1.42, s | 24.8 | 1.46, s | 30.2 |
| 29a | 4.77, d (11.2) | 66.5 | | | 1.41, s | 26.2 | 1.12, s | 23.0 | 1.08, s | 21.9 | 1.70, s | 24.4 |
| 29b | 4.41, d (11.2) | | | | | | | | | | | |
| 30a | 1.25, s | 20.3 | 1.29, s | 23.7 | 5.45, s | 121.6 | 1.25, s | 21.7 | 1.35, s | 21.7 | 1.34, s | 22.1 |
| 30b | | | | | 5.33, s | | | | | | | |
| 7-OMe | 3.78, s | 52.2 | | | 3.67, s | 53.3 | 3.71, s | 53.4 | 3.78, s | 53.1 | 3.78, s | 52.8 |
| Ac | 2.23, s | 169.8 | | | 1.99, s | 171.7 | | | | | | |
| | | 20.8 | | | | 21.4 | | | | | | |

2.4. Microplate assay for radical scavenging activity DPPH

Microplate DPPH assay was performed as described according to Luo, Zhou, Ma, and Fu (2014). Briefly, successive sample dilutions (standard stocks of different samples 5 mM) in a 96-well plate afforded DPPH solution (40 μ M in methanol) in a total volume of 0.2 mL. The absorbance value was recorded at 550 nm with a microplate read in triplicate. Results were determined each 5 min until 60 min in order to measure kinetic behaviour of the reaction. The percentage of remaining DPPH was calculated using the following: $\%DPPH_{rem} = 100 \times ([DPPH]_{sample}/[DPPH]_{blank})$.

A calibrated Trolox (3.9 mM initial concentration) standard curve was also made. The percentage of remaining DPPH against the standard concentration was plotted in an exponential regression to obtain the amount of antioxidant necessary to decrease the initial DPPH concentration by 50% (IC₅₀).

2.5. 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) (ABTS) radical cation decolorisation assay

ABTS⁺ scavenging activity was determined by the method of Gasca, Cabezas, Torras, Bastida, and Codina (2013). The radical cation was generated by the reaction between 7 mM ABTS in H₂O and 2.45 mM potassium persulphate, stored at room temperature in the dark for 16 h. Before usage, the solution was diluted with phosphate buffer (pH 7.4, 0.05 M) to reach an absorbance of 0.800 ± 0.035 at 734 nm. Different concentrations of isolated compounds solution in methanol were added into 1 mL of ABTS⁺ solution. The mixture was incubated in the dark at 37 °C. After 30 min of incubation, the percentage inhibition of absorbance at 734 nm was calculated for each concentration relative to a blank absorbance (methanol). All determinations were carried out in triplicate with Trolox as reference. The capability to scavenge the ABTS⁺ was calculated with the following equation: ABTS⁺ scavenging effect (%) = $100 - [(A_{sample}/A_{control}) \times 100]$, where A_{sample} is absorbance of the remaining concentration of ABTS⁺ in the presence of different compounds and $A_{control}$ is the initial concentration of the ABTS⁺. The stock concentrations of Trolox and tested compounds are the same as reported in DPPH assay.

2.6. Anti-inflammatory assay in vitro

The anti-inflammatory activities were measured according to the literature with slight modifications (Gao et al., 2015). The reaction system was incubated at 25 °C for 5 min, by sequential addition of the buffer, haem, pure compounds, and Cox-1 or Cox-2 into the system followed by mixing with arachidonic acid and TMPD. The optical density was recorded at 590 nm after another 15 min of incubation at 25 °C. SC-560 and NS-398 were used as positive controls which gave the inhibitions of Cox-1 (63.5%) and Cox-2 (97.0%) respectively (Table 2).

2.7. Cytotoxicity assay in vitro

The cytotoxic potential of compounds 1–12 was evaluated by modified MTT method (Chen, Hung, Sung, Chen, & Kuo, 2011).

Table 2 – In vitro free radical scavenging and anti-inflammatory activities of compounds 1–12.

| Compounds | Free radical scavenging activity ^a | | Anti-inflammatory activity ^b | |
|-----------|---|------------------------------------|---|-------|
| | DPPH IC ₅₀ | ABTS ⁺ IC ₅₀ | COX-1 | COX-2 |
| 1 | – | – | 88.1 | 35.6 |
| 2 | – | – | 92.7 | 39.3 |
| 3 | – | – | 91.1 | 40.2 |
| 4 | 104.0 | 52.2 | 95.2 | 40.1 |
| 5 | 62.1 | 124.7 | 44.3 | 21.4 |
| 6 | 244.7 | 256.1 | 53.1 | 24.4 |
| 7 | 59.2 | 119.8 | <0 | <0 |
| 8 | 51.3 | 109.7 | <0 | <0 |
| 9 | 71.0 | 160.1 | <0 | <0 |
| 10 | 73.1 | 167.3 | 30.2 | 19.7 |
| 11 | – | – | 89.8 | 37.6 |
| 12 | – | – | 44.3 | 20.7 |
| SC-560 | | | 63.5 | |
| NS-398 | | | | 97.0 |
| Trolox | 42.8 | 80.1 | | |

^a All compounds and reference drug are expressed as IC₅₀ values in μ M. (–) No activity.

^b Percent inhibition (all compounds and reference drugs concentration: 100 μ M).

Nine tumour cell lines (A549, BGC-823, CHG-5, HCT15, HeLa, HepG2, MDA-MB-231, SHG-44, and SGC-7901 cells) were cultured on RPMI-1640 medium supplemented with 10% foetal bovine serum, 100 μ g/mL streptomycin and 100 U/mL penicillin in culture flasks in humidified atmosphere with 5% CO₂ at 37 °C. For the cytotoxic tests, cells were harvested in exponential growth stage by trypsin digestion and centrifuging at $180 \times g$ for 3 min, then resuspended in fresh medium at a cell density of 5×10^4 cells per mL. The cell suspension was dispensed into a 96-well microplate at 100 μ L/well, and incubated at 37 °C in humidified atmosphere with 5% CO₂ for 24 h, and then treated with test compounds at various concentrations (0, 1, 10, 100 μ M). After 48 h of treatment, 50 μ L of 1 mg/mL MTT solution was added into each well, and further incubated for 4 h. The cells in each well were solubilised with DMSO (100 μ L for each well) and the optical density was recorded at 570 nm. All drug doses were examined at least three times with Adriamycin as the positive control. The IC₅₀ values were derived from the mean OD values of the triplicate tests versus drug concentration curves and expressed as means \pm standard deviation.

3. Results and discussion

3.1. Structure elucidation of the new limonoids

Compound 1 was obtained as a white amorphous powder. Its molecular formula was deduced as C₂₉H₃₈O₉ by HR-ESI-MS spectrum, corresponding to 11 unsaturation degrees. The ¹H NMR spectrum of 1 exhibited the presence of resonances for a methoxy proton at δ_H 3.78 (s), four tertiary methyls [δ_H 1.02, 1.05, 1.08, and 1.25 (each 3H, s)], one oxygenated methylene at δ_H 4.77 and 4.41, three characteristic protons attached to a carbon adjacent to an oxygen atom [δ_H 3.46 (s), 3.80 (dd, $J = 11.4, 5.0$ Hz)

and 3.95 (m)], and a β -substituted furan ring group [δ_{H} 6.21 (br s), 7.15 (br s), and 7.41 (s)]. Analyses of its ^{13}C NMR spectrum displayed 29 carbon resonances due to six methyl (one oxygenated), five sp^3 methylene (one oxygenated), nine methine (three oxygenated and three olefinic), seven quaternary (one ketone and one olefinic), and two ester carbonyl carbons. These functionalities (two double bonds and three carbonyl) accounted for 5 out of the 11 degrees of unsaturation. The remaining 6 degrees of unsaturation required **1** to be hexacyclic. Strong HMBC correlations of H-12 (δ_{H} 2.44 and 1.62), H-16 (δ_{H} 2.28 and 1.81), H-17 (δ_{H} 2.76), and H-30 (δ_{H} 1.25) with C-14 (δ_{C} 74.3) and H-17 with C-15 (δ_{C} 54.9) and C-21 (δ_{C} 139.3) clearly indicated the five-membered ring D to have a 14,15-epoxy group. A ketone carbon resonance (δ_{C} 208.8) was assigned to C-3 as judged from the HMBC correlations of Me-28/C-3 and Me-29/C-3. The oxygen bridge could then be located between C-1 and C-11 due to the HMBC correlation of H-1 (δ_{H} 3.80) with C-3 and C-9 (δ_{C} 63.5) and of H-11 (δ_{H} 3.95) with C-10 (δ_{C} 49.0) and C-13 (δ_{C} 41.6), which was further confirmed by the correlations of H-1/H-2 and H-9/H-11/H-12 in ^1H - ^1H COSY spectrum. These spectral evidences indicated that **1** might be a ring B-seco limonoid bearing the same C, D and E rings with a 14 β ,15 β -epoxide identical with toonafolin (**11**) (Liu et al., 2012), obtained also from the same plant source. The only significant difference between **1** and toonafolin was the presence of an acetyl group at C-29 in **1**, which was further confirmed by the HMBC correlation of the oxygenated methylene protons at δ_{H} 4.77 and 4.41 (H-29) with the carbonyl carbon (δ_{C} 169.8) of the acetyl group. On the basis of the observation of ROESY data similar to those of **11**, the stereochemistry of **1** was expected to be the same. Ring A should be nearer to a chair conformation, in which H-1 and H₃-19 are eclipsed which was supported by ROESY correlations of H-1 β (δ_{H} 3.80) with H-2 β (δ_{H} 2.66) and H₃-19 (δ_{H} 1.08). The ROESY correlations of H-1/H-2 β , H-1/H₃-19 β , H-11/H₃-19 β , H-11/H-12 β , and H-11/H₃-30 β suggested that H-1 and H-11 were β -orientated. Moreover, the existence of a correlation from H₃-19 β to H-11 (δ_{H} 3.95) confirmed that H-11 is in the β - and the oxide ring in the α -configuration. The configuration of the 14,15-epoxide was deduced by NMR spectroscopic comparison with **1** and **11**, which showed similar chemical shifts and proton coupling patterns. Consequently, compound **1** was unambiguously determined as toonasinenine A.

Compound **2** corresponded to molecular formula $\text{C}_{27}\text{H}_{32}\text{O}_8$, which was determined by positive HR-ESI-MS data. The IR spectrum displayed absorption bands for saturated carbonyl (1740 cm^{-1}), aldehyde (1721 cm^{-1}), unsaturated carbonyl (1681 cm^{-1}) and olefinic (1636 cm^{-1}) groups. Comparison of NMR data of compounds **2** and **1** indicated that they were almost the same except for the ring A signals. In NMR experiments, one $\text{C}=\text{C}$ [δ_{C} 185.2 (s), 98.2 (δ_{H} 5.47, s, 1H)] was found and the signal of C-3 in **2** was upfield shifted to δ_{C} 195.8. These data established that one α,β -unsaturated carbonyl group was located at C-1, C-2 and C-3. This deduction was further confirmed by the UV absorptions at λ_{max} 210 and 259 nm and by the HMBC correlations of H-2 to C-4 and C-10. Additionally, the chemical shifts of an aldehyde group [δ_{C} 199.8 and δ_{H} 9.82 (s)] in **2** taking the place of oxygenated methylene (C-29) in **1**. Therefore, **2** was structurally elucidated to be toonasinenine B.

The molecular formula of the compound **3** was assigned as $\text{C}_{33}\text{H}_{42}\text{O}_{13}$ on the basis of the quasimolecular ion peak m/z

669.2517 in positive HR-ESI-MS. The ^1H and ^{13}C NMR data (Table 1) of **3** were almost identical to those of **1** except that the C-atom signal assignable to C-12 was shifted downfield from δ_{C} 41.0 in **1** to δ_{C} 75.5 in compound **3**, implying that there was one OAc group located at C-12. This was further confirmed by the cross-peaks between H-12 (δ_{H} 5.49, dd, $J = 16.0, 10.8\text{ Hz}$) with C-9, C-14 and the carbonyl carbon (δ_{C} 172.3) of the acetyl in the HMBC spectrum. The above evidences led to conclusion that the structure of compound **3** was determined as toonasinenine C.

Compound **4** possessed the molecular formula $\text{C}_{25}\text{H}_{32}\text{O}_{10}$ as determined by analyses of NMR data and verified by the high-resolution mass spectrometry. The typical NMR patterns, especially the presence of the β -substituted furan ring and four tertiary methyl groups, implied that **4** was likely to be a norlimonoid (Liao et al., 2009). Comparison of its NMR spectroscopic data with those of toonaciliatin L (Liu et al., 2011) suggested that they are structural congeners. The mere ^{13}C NMR difference was the NMR resonances corresponding to a methine (δ_{C} 46.7; δ_{H} 2.36 and 1.55, H-12) replaced those of the oxygenated methylene in toonaciliatin L. In the ROESY spectrum, the key cross-peak of H-3/H-2 β elucidated that H-3 was axial towards the β -direction, which was also elucidated by the upfield shift for the carbon resonance of C-28 due to the γ -gauche effect of 3-OH. All available evidence suggested the structure of toonasinenine D.

Compound **5** exhibited a quasimolecular ion peak at m/z 535.2303 [$\text{M} + \text{Na}$] $^+$ (calc. 535.2308) in positive HR-ESI-MS spectrum, which corresponded to the molecular formula $\text{C}_{29}\text{H}_{36}\text{O}_8$. The ^1H and ^{13}C NMR data (Table 1) of compound **5** showed many similarities to those of 12-deacetoxytoonacilin, indicating that they are structural analogues with the only difference being the presence of OH-6 in **5** (Liu et al., 2012). This was confirmed by the HMBC correlations of H-6 (δ_{H} 4.61) to C-4 (δ_{C} 59.5) and C-10 (δ_{C} 42.0), and of OMe (δ_{H} 3.67) to C-7 (δ_{C} 178.4). The β -oriented configuration of the OH at C-6 in **5** was deduced by comparing the chemical shifts of H-6 and C-6, and the coupling pattern with its analogues 12-deacetoxytoonacilin and substantiated by its ROESY spectrum. On the basis of these results, the structure of **5** can be represented as toonasinenine E.

Compound **6** was isolated as a white amorphous powder with molecular formula $\text{C}_{27}\text{H}_{38}\text{O}_9$, as determined by HR-ESI-MS, showing an [$\text{M} + \text{Na}$] $^+$ ion at m/z 529.2413. Analysis of the ^1H and ^{13}C NMR spectra suggested the presence of a disubstituted epoxy group (δ_{C} 57.9, 58.2; δ_{H} 3.23, 3.11), which was assigned to be α -oriented 1,2-epoxy on the basis of HMBC correlations of Me-19/C-1, H-2/C-10, and H-2/C-4, and the ROESY cross-peaks of H-1 with H-11 α , H-11 β and H₃-30, and of H-2 with H-3 (Fig. 2). Comparison of NMR data of **6** and toonacilianin D (**12**) indicated that they were similar in structure, except that signal due to C-6 was shifted downfield to δ_{C} 72.8 in **6**, suggesting that there should be a hydroxy group located at C-6 (Liu et al., 2011). This deduction was further confirmed by the cross-peaks between H-6 (δ_{H} 4.42), and C-4 and C-10 in the HMBC spectrum. The other three hydroxyl groups were placed on C-3 (δ_{C} 74.0), C-8 (δ_{C} 78.0), and C-12 (δ_{C} 77.2), respectively, by the key HMBC correlations of H₃-28 and H₃-29 to C-3, of H-11 and H-15 to C-8, and of H-12 to C-9, C-14, and C-17, respectively. The ROESY correlations from both H₃-28 and H₃-29 to H-3 indicated gauche relationships of H₃-28/H-3 and H₃-29/H-3, and that H-3 was thus equatorial and towards the β -face.




Fig. 2 – Key HMBC (↷) correlations of compounds 1, 5, 6, 8 and 10.

The strong ROESY correlations of H₃-30/H-11 β and H-12/H-17 β unambiguously indicated the β -configurations of H-12 and H₃-30. Thus, the structure of 6 was established as depicted.

The positive HR-ESI-MS of compound 7 was consistent with the formula C₂₇H₃₆O₈, corresponding to 10 degrees of unsaturation. The similarities between the ¹³C NMR of 7 and 6 suggested that they were structural congeners and that the major differences occurred in ring A. The resonances at δ_c 204.8 (s), 152.6 (d), 124.6 (d), and 46.5 (s) of ring A were similar to those of ring A of 5, which indicated that an α,β -unsaturated ketone group was located at C-1, C-2 and C-3 in the ring A of 7. In the HMBC spectrum, correlations of H-6 to C-4, C-10, and C-7 suggested that a hydroxyl group was linked to C-6. The α -configuration of H-6 orientation was confirmed by the correlations between H-6/H-9 and H-9/H₃-18 in the ROESY spectrum. Thus, compound 7, named toonasinene G, was determined as shown in Fig. 1.

Compound 8 was isolated as a white amorphous powder. The molecular formula C₂₇H₃₈O₆ was established by a positive ion HR-ESI-MS. The infrared spectrum exhibited the characteristic absorptions of OH group (3434 cm⁻¹) and a C=O double bond at 1647 cm⁻¹. In ¹³C NMR spectrum, the characteristic signals for C-8 (δ_c 69.4), C-14 (δ_c 79.0) and C-15 (δ_c 76.2) suggested the 8,14-epoxide ring and a hydroxyl at C-15 in 8, which was further confirmed by the presence of a spin system of O-H-15/H₂-16/H-17 in ¹H-¹H COSY and the HMBC correlation of H-11, H-15 with C-8 and H-16 and H-17 with C-14. The ROESY correlations of H₃-19/H₃-30 and H-15/H₃-18 suggested that the 8,14-epoxide ring and the OH-15 were in α - and β -orientations respectively. Careful analysis of the NMR spectra suggested that 8 was also a ring B-*seco* limonoid bearing the same C, D and E rings with a 8,14-epoxy group as in toonaciliatin E (Liu et al., 2011). The hydroxyl group on C-3 (δ_c 77.9) was elucidated by the key HMBC correlations of Me-28 and Me-29 to C-3. The ROESY cross-peaks from both Me-28 and Me-29 to H-3 indicated gauche relationships of Me-28 to H-3 and Me-29 to H-3, and that H-3 was thus β -orientations. Consequently, compound 8 was unambiguously determined as toonasinene H.

Compound 9 was assigned a molecular formula C₂₇H₃₆O₈ established by a positive HR-ESI-MS. The ¹H NMR spectrum displayed six methyls (including one methoxy), one β -substituted furan ring (δ_H 6.17, 7.13, and 7.36), and two olefinic methines [δ_H 6.28 and 5.97 (each, d, J = 11.8 Hz)]. Additionally, an α,β -unsaturated lactone (δ_c 166.7, 150.1, 121.5 and 83.6) was distinguished by analysis of its ¹³C NMR and

HMBC data. The above evidence showed that compound 9 was a tetranortriterpenoid sharing some similarity to toonayunnanin E (Liu et al., 2012). The NMR difference indicated that the acetyl group at C-6 in toonayunnanin E was replaced by a hydroxyl group in 9, which was further confirmed by the upfield shift of C-6 to 70.1 in 9 and the HMBC correlations of H-6 (δ_H 4.69) with C-4 (δ_c 83.6) and C-10 (δ_c 49.1). The 14,15-epoxide ring and a hydroxyl group at C-8 in 9 was elucidated by the HMBC correlations from H₃-18, H-16, H-17 and H₃-30 to C-14 and from H-17 to C-15. The ROESY correlation of H₃-30/H₃-19 β suggested the α -configuration of 8-OH. The singlet of H-6 suggested that the dihedral angle between H-6 and H-5 is 90° in its preferred conformation, and the ROESY correlations of H-6/H-5, H-6/H-9, and H-6/H₃-28 were consistent with a 6R* configuration. The configuration of the 14,15-epoxide ring was the same as 1 according to their similar ROESY correlations. Finally, the structure of 9 named toonayunnanin J was established.

Compound 10 gave a quasimolecular ion peak at *m/z* 511.2693 [M + H]⁺ (calc. 511.2696) in the HR-ESI-MS, accounting for a molecular formula C₃₀H₃₈O₇. The IR absorptions at 1730 and 1615 cm⁻¹ and the UV absorption at λ_{max} 225 nm suggested an α,β -unsaturated ester. The presence of an isobutyryloxy group, five methyls, three methylenes, ten methines (five olefinic, three of which due to β -substituted furan ring), and seven quaternary carbons (one olefinic attributed to β -substituted furan ring, two oxygenated, and two carbonyl), were indicated by analysis of the ¹H, ¹³C NMR, and DEPT data. The ketonic carbonyl group located at C-7 was confirmed by correlations of H₃-30, H-9, and H-5 to C-7 in the HMBC experiment. These data showed that 10 was an evoludolone-class limonoid possessing the same ring fusion as 9. The ¹³C NMR signals of 14,15-epoxide group [δ_c 69.7 (s), and 55.4 (δ_H 3.56, s, 1H)] were superimposable over those of 9. So the stereochemistry of the 14,15-epoxide was assigned to be in β -orientation. The HMBC correlations from H-12, H₃-3', H₃-4', H-2' to C-1' indicated that the isobutyryloxy group was attached to C-12. In the ROESY spectrum of 10, the correlations of H-12 with H₃-19 β and H-17 β , and of H-7 with H₃-30 β and H-14, suggested that H-7 and H-12 were β -orientated. Thus, the structure of 10 was determined as toonayunnanin J.

The structural elucidations from the spectral data of the 2 known compounds, 11 and 12, are in agreement with those found in the literatures and characterised as toonafolin (11) and toonacilianin D (12) (Liu et al., 2011).

3.2. Radical scavenging activity

Antioxidant evaluation of 1–12 by both DPPH and ABTS assays (Table 2) showed that compounds 5 and 7–10 had significant antiradical activities to the tested radical of DPPH and ABTS⁺. Comparing the IC₅₀ values with that shown by Trolox in the two assays, compounds 4 seemed to possess stronger antiradical activities on radicals of ABTS⁺ but lower scavenging activity on DPPH assays than other compounds.

3.3. Anti-inflammatory activity

The compounds 1–12 were tested *in vitro* for their anti-inflammatory activities (Table 2). Among the assayed compounds, 1–4 and 11 with 14 β ,15 β -epoxide and 1 α ,11 α -oxygen bridge displayed comparable selective inhibition of Cox-1 (>88%) with positive control SC-560, while alkaloids 5, 6 and 12 exhibited modest selective inhibition of Cox-1. The other compounds had no anti-inflammatory activities or selective inhibition of Cox-1 comparable to those of 1–4 and 12 although they possess the similar limonoid skeleton.

3.4. Cytotoxic activity on cancer cells

The cytotoxic activities of the isolated compounds were examined against A549 cells (human lung cancer), BGC-823 cells (human gastric carcinoma), CHG-5 (glioma), HCT15 cells (human colon cancer), HeLa cells (human cervical cancer), HepG2 cells (Human hepatocellular carcinoma), MDA-MB-231 cells (human breast cancer), SHG-44 (glioma), and SGC-7901 cells (human gastric adenocarcinoma) (Table 3). Among all compounds, B-seco limonoids 1–4 and 11 bearing 14 β ,15 β -epoxide and 1 α ,11 α -oxygen bridge possessed the higher cytotoxic potential (IC₅₀ value less than 15 μ M) than 5–7 and 12 with only 14 β ,15 β -epoxide (IC₅₀ value less than 25 μ M) against all tested tumour cell lines except glioma cell lines. Additionally, limonoids 9 and 10 with a 14 β ,15 β -epoxide in which A ring contain an α,β -unsaturated lactone displayed particular cytotoxicities against two glioma cell lines.

The tender leaves of *T. sinensis* are used as a nutritious and functional food for treating enteritis, gastric ulcers, rheumatoid

arthritis, cervicitis, urethritis, tympanitis, dysentery, itchinness, and cancer. In screening radical scavenging activities, compounds 5 and 7–10 exhibited significant antiradical activities to the tested radical of DPPH and ABTS⁺. Due to their intrinsic structural variety, we were interested in establishing that α,β -unsaturated ketone moiety in the ring A, capable of donating an electron and hydrogen atom by resonance hybrid and keto-enol Keto-enol tautomerisation, may strengthen the actions of radical scavenging character. Compounds 4 exhibited more significant antiradical activities on radicals of ABTS⁺ than on DPPH assays, which may be elucidated by the mechanism difference that the ABTS⁺ reactions involve electron transfer and take place at a much faster rate compared to DPPH radicals. 4 possesses high amount of phenols which can take part in electron transfer and hydrogen atom transfer reactions with many oxidising free radicals. In anti-inflammatory and cytotoxic bioassays, limonoids 1–4 and 11 bearing a 14 β ,15 β -epoxide have higher activities relative to 5–7 and 12 with 8 α ,14 α -epoxide. Among them, 4 exhibited the most significant anti-inflammatory and cytotoxic activities with the lowest IC₅₀. These result suggested the 14 β ,15 β -epoxide and 1 α ,11 α -oxygen bridge may be important and the γ -lactone between C-4 and C-5 maybe strengthen for their anti-inflammatory and cytotoxic actions for this class of limonoids. In addition, limonoids 5 showed stronger cytotoxicities than 6, which indicated the 1,2-epoxy might be weaken the cytotoxic potential. Limonoids 9 and 10 displayed cytotoxic activities against gliom cell lines (IC₅₀: 18.6 and 28.0 μ M; 22.7 and 31.4 μ M respectively). These result suggested that an α,β -unsaturated lactone in A ring should be important for their particular cytotoxicities against gliom cell lines.

4. Conclusions

Ten new limonoids, toonasinines A–J (1–10), together with 2 known compounds, toonafolin (11) and toonacilianin D (12) were isolated from the stems of *T. sinensis*. All the limonoids were *in vitro* evaluated for their radical scavenging activities of ABTS⁺ and DPPH, anti-inflammatory for Cox-1 or Cox-2,

Table 3 – Cytotoxicities of compounds 1–12 against nine human tumour cell lines (IC₅₀ \pm SD, μ M).

| Compounds | Cell lines | | | | | | | | |
|-------------|----------------|-----------------|----------------|----------------|----------------|-----------------|----------------|----------------|-----------------|
| | A-549 | BGC-823 | CHG-5 | HCT15 | HeLa | HepG2 | MDA-MB-231 | SGC-7901 | SHG-44 |
| 1 | 13.3 \pm 3.0 | – | 14.6 \pm 4.6 | 14.7 \pm 4.3 | 14.0 \pm 4.3 | 13.9 \pm 3.7 | 14.2 \pm 4.0 | 13.1 \pm 4.9 | – |
| 2 | 5.7 \pm 2.7 | 33.7 \pm 7.8 | 5.0 \pm 2.1 | 5.7 \pm 2.3 | 6.2 \pm 2.7 | 5.5 \pm 1.6 | 6.0 \pm 1.1 | 6.0 \pm 2.1 | – |
| 3 | 9.7 \pm 7.4 | – | 8.3 \pm 5.7 | 10.1 \pm 6.4 | 8.1 \pm 5.1 | 9.1 \pm 8.8 | 9.4 \pm 7.3 | 9.4 \pm 8.1 | – |
| 4 | 2.3 \pm 0.6 | 27.9 \pm 9.6 | 2.8 \pm 0.7 | 2.6 \pm 0.5 | 2.9 \pm 0.8 | 3.0 \pm 1.1 | 2.7 \pm 0.9 | 2.1 \pm 0.7 | 44.9 \pm 10.3 |
| 5 | 20.4 \pm 4.6 | – | 19.9 \pm 5.3 | 21.5 \pm 6.8 | 23.6 \pm 5.0 | 23.4 \pm 4.5 | 21.0 \pm 3.5 | 21.1 \pm 4.6 | – |
| 6 | 23.3 \pm 5.0 | – | 23.9 \pm 6.2 | 24.6 \pm 6.1 | 24.7 \pm 7.1 | 24.0 \pm 5.3 | 22.4 \pm 4.4 | 24.2 \pm 5.0 | – |
| 7 | 18.4 \pm 4.9 | – | 19.5 \pm 5.3 | 18.4 \pm 5.7 | 21.6 \pm 5.3 | 21.7 \pm 5.0 | 20.8 \pm 5.3 | 19.9 \pm 4.0 | – |
| 8 | 34.8 \pm 7.2 | – | 31.2 \pm 8.6 | 33.2 \pm 8.7 | 31.4 \pm 7.1 | 31.6 \pm 6.1 | 33.2 \pm 8.1 | 33.6 \pm 7.9 | – |
| 9 | 44.3 \pm 8.2 | 18.6 \pm 4.0 | – | – | – | 43.2 \pm 10.1 | – | 39.1 \pm 9.7 | 28.0 \pm 5.3 |
| 10 | – | 22.7 \pm 4.1 | – | 49.7 \pm 9.1 | – | 46.7 \pm 9.8 | – | – | 31.4 \pm 7.4 |
| 11 | 9.7 \pm 2.7 | 47.1 \pm 13.1 | 9.6 \pm 1.3 | 11.2 \pm 3.4 | 9.0 \pm 2.1 | 10.7 \pm 0.6 | 9.8 \pm 2.4 | 10.5 \pm 2.9 | – |
| 12 | 19.0 \pm 3.0 | – | 20.0 \pm 2.6 | 22.0 \pm 2.9 | 22.4 \pm 4.7 | 22.8 \pm 5.1 | 23.8 \pm 4.6 | 20.3 \pm 4.8 | – |
| Doxorubicin | 0.01 | 0.02 | 0.03 | 0.05 | 0.04 | 0.03 | 0.02 | 0.04 | 0.04 |

The assay was done using three replicates and repeated four times. (–) IC₅₀ > 50 μ M.

cytotoxicities against eight tumour cell lines. Compound 4 possess higher antiradical activities than other compounds on radicals of ABTS⁺. Compounds 5 and 7–10 possessed strong scavenging activities of ABTS⁺ and DPPH. Limonoids 1–4 and 11 with a 14 β ,15 β -epoxide and a 1 α ,11 α -oxygen bridge showed selective inhibition for COX-1 (>88%) and cytotoxicities against all tested tumour cell lines except glioma cell lines. Limonoids 9 and 10 with a 14 β ,15 β -epoxide in which A ring contain an α , β -unsaturated lactone displayed particular cytotoxic activities against glioma cell lines. Taken together, the amounts of limonoids are an important index to evaluate the therapeutic effects for the medium polar extracts of *T. sinensis*.

Acknowledgments

The above research was made possible by the grant from the National Natural Science Foundation of China (31300370) and the Scientific Planning Project of the Applied Basic Research of Yunnan Province (S2012FZ0005).

REFERENCES

- Chang, H. L., Hsu, H. K., Su, J. H., Wang, P. H., Chung, Y. F., Chia, Y. C., Tsai, L. Y., Wu, Y. C., & Yuan, S. S. (2006). The fractionated *Toona sinensis* leaf extract induces apoptosis of human varian cancer cells and inhibits tumor growth in a murine xenograft model. *Gynecologic Oncology*, 102, 309–314.
- Chen, C. J., Michaelis, M., Hsu, H. K., Tsai, C. C., Yang, K. D., Wu, Y. C., Cinatl, J., Jr., & Doerr, H. W. (2008). *Toona sinensis* Roem tender leaf extract inhibits SARS coronavirus replication. *Journal of Ethnopharmacology*, 120(1), 108–111.
- Chen, G. H., Huang, F. S., Lin, Y. C., Hsu, C. K., & Chung, Y. C. (2013). Effects of water extract from anaerobic fermented *Toona sinensis* Roemer on the expression of antioxidant enzymes in the Sprague–Dawley Rats. *Journal of Functional Foods*, 5, 773–780.
- Chen, J. J., Hung, H. C., Sung, P. J., Chen, I. S., & Kuo, W. L. (2011). Aporphine alkaloids and cytotoxic lignans from the roots of *Illigera luzonensis*. *Phytochemistry*, 72, 523–532.
- Chen, Y. C., Chien, L. H., Huang, B. M., & Chia, Y. C. (2014). *Toona sinensis* (aqueous leaf extracts) induces apoptosis through the generation of ROS and activation of intrinsic apoptotic pathways in human renal carcinoma cells. *Journal of Functional Foods*, 7, 362–372.
- Chen, Y. C., Liang, Y. L., Huang, Y. L., & Huang, B. M. (2015). Mechanism of *Toona sinensis*-stimulated adrenal steroidogenesis in primary rat adrenal cells. *Journal of functional foods*, 14, 318–323.
- Cheng, K. W., Yang, R. Y., Tsou, S. C. S., Lo, C. S. C., Ho, C. T., Lee, T. C., & Wang, M. F. (2009). Analysis of antioxidant activity and antioxidant constituents of Chinese toon. *Journal of Functional Foods*, 1, 253–259.
- Edmonds, J. M., & Staniforth, M. (1998). *Toona sinensis* (Meliaceae). *Curtis's Botanical Magazine*, 15, 186–193.
- Gao, C., Huang, X. X., Bai, M., Wu, J., Li, J. Y., Liu, Q. B., Li, L. Z., & Song, S. J. (2015). Anti-inflammatory sesquiterpene pyridine alkaloids from *Tripterygium wilfordii*. *Fitoterapia*, 105, 49–54.
- Gasca, C. A., Cabezas, F. A., Torras, L., Bastida, J., & Codina, C. (2013). Chemical composition and antioxidant activity of the ethanol extract and purified fractions of cadillo (*Pavonia sepioides*). *Free Radicals and Antioxidants*, 3, S55–S61.
- Hseu, Y. C., Chen, S. C., Lin, W. H., Hung, D. Z., Lin, M. K., Kuo, Y. H., Cho, H. J., Wang, L., & Yang, H. L. (2011). *Toona sinensis* (leaf extracts) inhibit vascular endothelial growth factor (VEGF)-induced angiogenesis in vascular endothelial cells. *Journal of Ethnopharmacology*, 134(1), 111–121.
- Hsiang, C. Y., Hseu, Y. C., Chang, Y. C., Kumar, K. J., Ho, T. Y., & Yang, H. L. (2013). *Toona sinensis* and its major bioactive compound gallic acid inhibit LPS-induced inflammation in nuclear factor-kappaB transgenic mice as evaluated by in vivo bioluminescence imaging. *Food Chemistry*, 136, 426–434.
- Hsieh, T. J., Tsai, Y. H., Liao, M. C., Du, Y. C., Lien, P. J., Sun, C. C., Chang, F. R., & Wu, Y. C. (2012). Anti-diabetic properties of non-polar *Toona sinensis* Roem extract prepared by supercritical-CO₂ fluid. *Food and Chemical Toxicology*, 50, 779–789.
- Liao, J. W., Yeh, J. Y., Lin, Y. C., Wei, M. M., & Chung, Y. C. (2009). Mutagenicity and safety evaluation of water extract of fermented *Toona sinensis* roemor leaves. *Journal of Food Science*, 74(1), T7–T13.
- Liu, H. W., Tsai, Y. T., & Chang, S. J. (2014). *Toona sinensis* leaf extract inhibits lipid accumulation through up-regulation of genes involved in lipolysis and fatty acid oxidation in adipocytes. *Journal of Agricultural and Food Chemistry*, 62(25), 5887–5896.
- Liu, J. Q., Wang, C. F., Li, Y., Chen, J. C., Zhou, L., & Qiu, M. H. (2012). Limonoids from the leaves of *Toona ciliata* var. *yunnanensis*. *Phytochemistry*, 76, 141–149.
- Liu, J., Yang, S. P., Su, Z. S., Lin, B. D., Wu, Y., & Yue, J. M. (2011). Limonoids from the stems of *Toona ciliata* var. *henryi* (Meliaceae). *Phytochemistry*, 72, 2189–2196.
- Luo, Y. H., Zhou, Z. Q., Ma, S. C., & Fu, H. Z. (2014). Three new antioxidant furofuran lignans from *Callicarpa nudiflora*. *Phytochemistry Letters*, 7, 194–197.
- Malairajan, P., Gopalakrishnan, G., Narasimhan, S., Veni, K. J., & Kavimani, S. (2007). Anti-ulcer activity of crude alcoholic extract of *Toona ciliata* Roemer (heart wood). *Journal of Ethnopharmacology*, 110, 348–351.
- Poon, S. L., Leu, S. F., Hsu, H. K., Liu, M. Y., & Huang, B. M. (2005). Regulatory mechanism of *Toona sinensis* on mouse Leydig cell steroidogenesis. *Life Sciences*, 76(13), 1473–1487.
- Su, Y. F., Yang, Y. C., Hsu, H. K., Hwang, S. L., Lee, K. S., Lieu, A. S., Chan, T. F., & Lin, C. L. (2015). *Toona sinensis* leaf extract has antinociceptive effect comparable with non-steroidal anti-inflammatory agents in mouse writhing test. *BMC Complementary and Alternative Medicine*, 15, 70. doi:10.1186/s12906-015-0599-2.
- Wang, C. C., Tsai, Y. J., Hsieh, Y. C., Lin, R. J., & Lin, C. L. (2014). The aqueous extract from *Toona sinensis* leaves inhibits microglia-mediated neuroinflammation. *Kaohsiung Journal of Medical Sciences*, 30, 73–81.
- Wu, J. G., Peng, W., Yi, J., Wu, Y. B., Chen, T. Q., Wong, K. H., & Wu, J. Z. (2014). Chemical composition, antimicrobial activity against *Staphylococcus aureus* and a pro-apoptotic effect in SGC-7901 of the essential oil from *Toona sinensis* (A. Juss.) Roem. leaves. *Journal of Ethnopharmacology*, 154, 198–205.
- Yang, C. J., Chen, Y. C., Tsai, Y. J., Huang, M. S., & Wang, C. C. (2014). *Toona sinensis* leaf aqueous extract displays activity against sepsis in both in vitro and in vivo models. *Kaohsiung Journal of Medical Sciences*, 30, 279–285.
- Zhao, J., Zhou, X. W., Chen, X. B., & Wang, Q. X. (2009). α -glucosidase inhibitory constituents from *Toona sinensis*. *Chemistry of Natural Compounds*, 45, 244–246.